(1 R,3 S)-3-(1 H-Benzo[ d]imidazol-2-yl)-1,2,2-tri-methyl-cyclo-pentane-1-carb-oxy-lic acid as a new anti-diabetic active pharmaceutical ingredient

Acta Crystallogr E Crystallogr Commun. 2020 Aug 4;76(Pt 9):1407-1411. doi: 10.1107/S2056989020010439. eCollection 2020 Sep 1.

Abstract

The chiral title compound, C16H20N2O2, which can be used for producing active pharmaceutical ingredients for treatment of type 2 pancreatic diabetes and other pathologies dependent on insulin resistance, was prepared from (1R,3S)-camphoric acid and o-phenyl-enedi-amine. It crystallized from an ethanol solution in the chiral monoclinic P21 space group. The five-membered ring adopts a twisted conformation with the methyl-substituted C atoms displaced by -0.273 (5) and 0.407 (5) Å from the mean plane through the other three atoms. In the crystal, mol-ecules are linked by O-H⋯N hydrogen bonds, forming chains along the a-axis direction. Hirshfeld surface analysis and two-dimensional fingerprint plots were used to analyze the inter-molecular contacts present in the crystal.

Keywords: 1H-benzo[d]imidazol-2-yl-1,2,2-tri­methyl­cyclo­pentane-carb­oxy­lic acid; Hirshfeld surface; active pharmaceutical ingredient; anti-diabetic agents; crystal structure; type 2 diabetes.